Repare Therapeutics (RPTX) Competitors $1.32 0.00 (0.00%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX vs. PROK, FHTX, RZLT, ANNX, NVCT, AARD, MNPR, DRUG, SLRN, and OCGNShould you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include ProKidney (PROK), Foghorn Therapeutics (FHTX), Rezolute (RZLT), Annexon (ANNX), Nuvectis Pharma (NVCT), Aardvark Therapeutics (AARD), Monopar Therapeutics (MNPR), Bright Minds Biosciences (DRUG), Acelyrin (SLRN), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Repare Therapeutics vs. ProKidney Foghorn Therapeutics Rezolute Annexon Nuvectis Pharma Aardvark Therapeutics Monopar Therapeutics Bright Minds Biosciences Acelyrin Ocugen Repare Therapeutics (NASDAQ:RPTX) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Which has more risk & volatility, RPTX or PROK? Repare Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Do analysts rate RPTX or PROK? Repare Therapeutics currently has a consensus target price of $4.50, indicating a potential upside of 240.91%. ProKidney has a consensus target price of $5.00, indicating a potential upside of 616.33%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50ProKidney 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher valuation & earnings, RPTX or PROK? ProKidney has lower revenue, but higher earnings than Repare Therapeutics. ProKidney is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$53.48M1.06-$93.80M-$3.01-0.44ProKidney$306K667.66-$35.47M-$0.60-1.16 Does the media prefer RPTX or PROK? In the previous week, Repare Therapeutics' average media sentiment score of 1.73 beat ProKidney's score of -0.64 indicating that Repare Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Repare Therapeutics Very Positive ProKidney Negative Do institutionals & insiders have more ownership in RPTX or PROK? 85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 11.5% of Repare Therapeutics shares are owned by company insiders. Comparatively, 41.5% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor RPTX or PROK? Repare Therapeutics received 35 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 64.18% of users gave Repare Therapeutics an outperform vote while only 53.33% of users gave ProKidney an outperform vote. CompanyUnderperformOutperformRepare TherapeuticsOutperform Votes4364.18% Underperform Votes2435.82% ProKidneyOutperform Votes853.33% Underperform Votes746.67% Is RPTX or PROK more profitable? ProKidney has a net margin of 0.00% compared to Repare Therapeutics' net margin of -99.76%. ProKidney's return on equity of 0.00% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Repare Therapeutics-99.76% -40.87% -35.07% ProKidney N/A N/A -10.24% SummaryProKidney beats Repare Therapeutics on 9 of the 15 factors compared between the two stocks. Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPTX vs. The Competition Export to ExcelMetricRepare TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.62M$6.49B$5.33B$8.35BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-0.668.5626.7419.65Price / Sales1.06258.46394.49119.78Price / CashN/A65.8538.3234.62Price / Book0.266.406.744.50Net Income-$93.80M$143.98M$3.23B$248.32M7 Day Performance-1.49%0.06%0.13%-0.96%1 Month Performance3.13%1.81%8.83%10.86%1 Year Performance-57.42%-0.92%18.45%9.08% Repare Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPTXRepare Therapeutics3.0721 of 5 stars$1.32flat$4.50+240.9%-60.0%$56.62M$53.48M-0.66180Positive NewsPROKProKidney1.8023 of 5 stars$0.81+0.2%$5.00+518.5%-79.6%$236.62M$76,000.00-1.473Analyst UpgradeFHTXFoghorn Therapeutics2.4844 of 5 stars$4.21-5.0%$12.13+188.0%-33.4%$234.67M$22.60M-2.19120Gap DownRZLTRezolute2.6295 of 5 stars$3.80+6.4%$12.14+219.5%+38.8%$230.03MN/A-3.1140Analyst DowngradeANNXAnnexon1.855 of 5 stars$2.09+4.0%$12.50+498.1%-57.8%$229.30MN/A-1.9960Gap DownNVCTNuvectis Pharma2.2004 of 5 stars$10.95+10.9%$17.00+55.3%+49.2%$228.79MN/A-9.448AARDAardvark TherapeuticsN/A$10.43+5.5%$31.25+199.6%N/A$226.29MN/A0.0018Analyst DowngradeMNPRMonopar Therapeutics2.8903 of 5 stars$36.90-0.7%$55.33+50.0%+1,053.3%$225.64MN/A-18.7310News CoveragePositive NewsAnalyst UpgradeGap DownDRUGBright Minds Biosciences3.0163 of 5 stars$31.99-3.1%$83.25+160.2%+2,574.3%$225.34MN/A-188.17N/ANews CoveragePositive NewsAnalyst ForecastSLRNAcelyrin3.4778 of 5 stars$2.23-0.9%$9.60+330.5%N/A$225.13MN/A-0.91135Positive NewsOCGNOcugen1.1897 of 5 stars$0.77+1.5%$6.00+679.4%-46.9%$224.81M$4.52M-4.2880Positive News Related Companies and Tools Related Companies ProKidney Alternatives Foghorn Therapeutics Alternatives Rezolute Alternatives Annexon Alternatives Nuvectis Pharma Alternatives Aardvark Therapeutics Alternatives Monopar Therapeutics Alternatives Bright Minds Biosciences Alternatives Acelyrin Alternatives Ocugen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPTX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RPTX Stock Free RPTX Stock Alerts